Three years after Takeda chipped into Cerevance’s series A, the Big Pharma has come back for more. The duo is inking a research deal focused on identifying new protein targets in the central nervous system to develop new treatments for gastrointestinal disorders. The companies kept details close to the vest but said Cerevance could net more than $170 million in milestones per target.